Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS into Phase 2 Trials

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its clinical development of LUCID-MS, a proprietary therapy candidate for multiple sclerosis (MS) designed to target demyelination and protect or restore myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated, supporting progression into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with MS.

This development is significant because LUCID-MS aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation, potentially offering a differentiated, first-in-class approach. The company is strengthening operational support through a planned partnership with Allucent and engagement with neurological specialists. The positive Phase 1 results and IND submission mark a critical step toward addressing the underlying mechanisms of MS, a chronic autoimmune disease affecting approximately 2.8 million people worldwide.

Quantum BioPharma is a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its subsidiary Lucid Psycheceuticals Inc., it focuses on LUCID-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% stake and royalty payments of 7% of sales until $250 million, then 3% in perpetuity. Quantum BioPharma retains 100% rights to develop similar products for pharmaceutical and medical uses.

The advancement of LUCID-MS into Phase 2 trials underscores the potential for a novel therapeutic approach that could alter the disease course for MS patients. If successful, it could provide a treatment that not only manages symptoms but also reverses myelin damage, a key unmet need in MS care. Investors and the medical community will closely watch the upcoming Phase 2 trial results. For more information, visit the company's newsroom at https://ibn.fm/QNTM.